Gorbunov A S, Vaizova O E, Belousov M V, Pozdnyakova S V, Nesterov E A, Madonov P G
Research Institute of Cardiology, Tomsk Research Center, Russian Academy of Sciences, Tomsk, Russia.
Siberian State Medical University, Ministry of Health of the Russian Federation, Tomsk, Russia.
Bull Exp Biol Med. 2017 Nov;164(1):18-20. doi: 10.1007/s10517-017-3916-6. Epub 2017 Nov 9.
Intravenous injection of nonselective antagonists of opioid receptors (OR) naltrexone (5 mg/kg) and naloxone methiodide (5 mg/kg), selective δ-OR antagonist BNTX (0.7 mg/kg), selective δ-OR blocker naltriben (0.3 mg/kg), selective κ-OR antagonist norbinaltorphimine (2 mg/kg), and selective blocker of ORL1 opioid receptors JTC-801 (0.1 mg/kg) produced no effect on reperfusion injury to the heart in rats narcotized with α-chloralose. In contrast, selective μ-OR antagonist CTAP (1 mg/kg) limited the infarct size, although this effect was not observed at a lower CTAP concentration of 0.1 mg/kg. Probably, the myocardial infarct size-limiting effect of CTAP was associated with activation of the non-opioid receptors. It was hypothesized that endogenous OR agonists did not affect heart resistance to reperfusion injury in unadapted rats.
静脉注射阿片受体(OR)非选择性拮抗剂纳曲酮(5毫克/千克)和甲碘 naloxone(5毫克/千克)、选择性δ-OR拮抗剂BNTX(0.7毫克/千克)、选择性δ-OR阻滞剂纳曲苄(0.3毫克/千克)、选择性κ-OR拮抗剂 norbinaltorphimine(2毫克/千克)以及选择性ORL1阿片受体阻滞剂JTC-801(0.1毫克/千克),对用α-氯醛糖麻醉的大鼠心脏再灌注损伤没有影响。相比之下,选择性μ-OR拮抗剂CTAP(1毫克/千克)限制了梗死面积,尽管在较低的CTAP浓度0.1毫克/千克时未观察到这种效果。CTAP的心肌梗死面积限制作用可能与非阿片受体的激活有关。据推测,内源性OR激动剂不会影响未适应大鼠心脏对再灌注损伤的抵抗力。